Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis
Joint Authors
Jin, Jiangtao
Li, Yongfu
Du, Qi
Guo, Hong
Wei, Yuhan
Peng, Xinyi
Li, Yongyan
Li, Qin
Source
Journal of Immunology Research
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-18
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Background.
PD-1/PD-L1 inhibitors have made unprecedented progress in the treatment of cancer.
Methods.
A systemic search was conducted for randomized controlled trials that compared PD-1/PD-L1 inhibitor monotherapy or combination therapy with nonimmunotherapy.
Hazard ratios (HRs) of overall survival (OS) according to the sex, age, ECOG PS, smoking status, liver metastasis, PD-L1 expression, EGFR, and KRAS status of patients were analyzed.
Results.
Totally, 13 studies with monotherapy and 5 with combination regimens were included, and the pooled HRs of OS were 0.74 (P<0.001) and 0.64 (P<0.001), respectively.
EGFR wild-type patients could benefit from immunotherapy monotherapy (HR, 0.77; P<0.001) while those of the mutant type had no survival benefit (HR, 1.11; P=0.54), and the difference was statistically significant (interaction, P=0.005).
KRAS wild-type patients had no survival benefit from monotherapy (HR, 0.89; P=0.49).
For combination therapy, both male and female derived benefits but female had a significantly reduced risk of death (HR, 0.45; P<0.001) compared with male (HR, 0.73; P<0.001; interaction, P=0.004).
Nonsmokers derived more survival benefits from combination therapy (HR, 0.29; P<0.001) than smokers (HR, 0.63; P=0.001; interaction, P=0.02).
No significant difference was found between age, ECOG PS, liver metastasis, PD-L1 expression, and OS of both PD-1/PD-L1 inhibitor monotherapy and combination therapy.
Conclusions.
Both PD-1/PD-L1 inhibitor monotherapy and combination therapy significantly prolonged the OS of patients with advanced malignant tumors.
EGFR status for monotherapy and sex and smoking status for combination therapy were important predictors of survival benefits.
American Psychological Association (APA)
Wei, Yuhan& Li, Yongfu& Du, Qi& Peng, Xinyi& Jin, Jiangtao& Guo, Hong…[et al.]. 2020. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1187291
Modern Language Association (MLA)
Wei, Yuhan…[et al.]. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1187291
American Medical Association (AMA)
Wei, Yuhan& Li, Yongfu& Du, Qi& Peng, Xinyi& Jin, Jiangtao& Guo, Hong…[et al.]. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1187291
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1187291